Freedom To Operate, Inc. et al. vs COMPASS Pathfinder Limited

Rehearing:Decision on Request for Rehearing

EXPUNGED

Order: Denying POP Request

Ex. 3001

Notice: notice of receipt of POP request

REQUEST FOR REHEARING UNDER 37 C.F.R. 42.71

Institution Decision: Deny

Patent Owner's Sur-Reply to Petitioner's Reply to Patent Owner's Preliminary Response

Patent Owner's Updated Exhibit List

Email correspondence from Jason Valentine (counsel for Patent Owner) to counsel for Petitioner

Cohen Foundation website, available at https://web.archive.org/web/20220516063415/https:/www.steveandalex.org/psychedelic-projects/, printed to PDF (last visited 5/19/2022)

FTO Application for Tax Exempt Status

IRS Determination Letter

FTO Form 990

Declaration of Carey Turnbull

Petitioner's Reply to Preliminary Response

Petitioner's Updated Exhibit List

Petitioner's Reply to Patent Owner's Preliminary Response

Patent Owner's Updated Exhibit List

Transcript of Telephonic Hearing on April 27, 2022 before Hon. Judges Hulse, Snedden and Paulraj

Order: Conduct of the Proceeding 37 C.F.R. sec. 42.5

DECISION Granting Patent Owners Motions for Admission Pro Hac Vice of Adam M. Pivovar 37 C.F.R. sec 42.10

Patent Owner's Unopposed Motion for Pro Hac Vice Admission of Adam Pivovar

Patent Owner's Updated Exhibit List

Declaration of Adam M. Pivovar in Support of Unopposed Motion to Appear Pro Hac Vice on Behalf of Patent Owner

Biography of Adam M. Pivovar in Support of Unopposed Motion to Appear Pro Hac Vice on Behalf of Patent Owner

Patent Owner's Preliminary Response

In re Armodafinil Patent Litigation, MDL No. 10-md-2200-GMS, 2011 WL 9158436 (D. Del. July 25, 2011)

Willowood USA, LLC. V. BASF SE, No. IPR2018-01096, Paper 10 (P.T.A.B. Nov. 29, 2018)

Pharmacyclics LLC et al v. Fresenius Kabi USA, LLC, No. 1:18-cv-00192-CFC-CJB, D.I. 346 (D. Del. Feb. 3, 2020)

Forest Lab���ys, LLC v. Accord Healthcare Inc., No. 15-272-GMS, 2016 WL 6892094 (D. Del. Nov. 21, 2016)

USP 24, The United States Pharmacopeia (2000)

GlaxoSmithKline Intellectual Property Management Ltd. v. Sandoz, Inc., No. 11-1284-RGA, 2013 WL 1163759 (D. Del. Mar. 20, 2013)

Astrazeneca AB v. Andrx Labs, LLC, No. 14-8030 (MLC)(DEA), 2017 U.S. Dist. LEXIS 3990 (D.N.J. Jan. 11. 2017)

Philip Morris Prods., S.A. v. Rai Strategic Holdings, Inc., No. PGR2020-00071, 2022 WL 129099 (P.T.A.B. Jan. 10, 2022)

Schlumberger Tech. Corp. v. DynaEnergetics Europe GmbH, No. PGR2021-00089, 2021 WL 6338268 (P.T.A.B. Dec. 14, 2021)

Agarwal v. Jhunjhunwala, No. PGR2021-00071, 2021 WL 4812937 (P.T.A.B. Sept. 17, 2021)

Adello Biologics LLC v. Amgen Inc., No. PGR2019-00001, 2019 WL 1750943 (P.T.A.B. Feb. 14, 2019) (Precedential)

RPX Corp. v. Applications in Internet Time, LLC, No. IPR2015-01750, Paper 128 (P.T.A.B. October 2, 2020) (precedential)

Petition for Post Grant Review of U.S. Patent No. 10,519, 175, Kohn Associates PLLC v. Compass Pathways Limited, No. PGR2020-00030, Paper 1 (P.T.A.B. Feb. 21, 2020)

Declaration of Poncho Meisenheimer and Alex Sherwood, Kohn Associates PLLC v. Compass Pathways Limited, No. PGR2020-00030, Exhibit 1008

Freedom to Operate, About Psilocybin, available at https://freedomtooperate.org/home/about-psilocybin/

New Filing Challenges Compass Pathways' Infamous Patent on S. Love, Synthetic Psilocybin (Dec. 15, 2021), available at https://www.vice.com/en/article/pkpg7b/synthetic-psilocybin-patent-challenge-compass-pathways

J.C. Hu, 5 Questions for Carey Turnbull (Jan 31), available at https://themicrodose.substack.com/p/5-questions-for-carey-turnbull?s=r

Kohn & Associates PLLC Third Party Observations (Jan. 23, 2020)

FDA grants Breakthrough Therapy Designation to Usona Institute's psilocybin program for major depressive order (Nov. 22, 2019)

Freedom to Operate, Protecting Psychedelic Science & Medical Development for Public Benefit, available at https://freedomtooperate.org/

Petitioner's Amended Mandatory Notices, Kohn Associates PLLC v. Compass Pathways Limited, No. PGR2020-00030, Paper 21 (P.T.A.B. July 21, 2020)

Cisco Sys., Inc. v. Hewlett Packard Enters. Co., No. IPR2017-01933, 2018 WL 1364821 (P.T.A.B. Mar. 16, 2018)

Freedom to Operate, Donate Now, available at https://freedomtooperate.org/donate-now/

Preliminary Amendment dated July 2, 2020

Freedom to Operate, Letter from the Founder, available at https://freedomtooperate.org/home/letter-from-the-founder/#letterfromthefounder

Psychedelic Bulletin: COMPASS' "Infamous" Psilocybin Patent Challenged; atai Stock Price Tumbles as Lock-Up Expiry Date Arrives; UT Austin Launches Psychedelics Centre

Ceruvia Lifesciences, About Us, available at https://ceruvialifesciences.com/about-us/

B.More, About Us, available at https://bmoreinc.org/about-us/

Usona Institute, Usona Team, available at https://www.usonainstitute.org/usona-team/#board-of-directors

B.More, Funding Psilocybin: Making Recovery a Reality, available at https://bmoreinc.org/

March 9, 2022, 3rd party observations against pending claims from U.S. Patent Application No. 17/604,610

Preliminary Program for Global Summit on Psychedelic-Assisted Therapies and Medicine, May 26-29, 2022 ��� Hilton Toronto, ON

Notice: acceptance corrected petition

Patent Owner's Mandatory Notices Under 37 CFR 42.8

Patent Owner's Power of Attorney

Bernstein J. Polymorphism in Molecular Crystals- International Union Of Crystallography, Oxford, 2002 (Corrected Version)

Triclinic Labs SOP Controlled Substances (Corrected Version)

Notice: defective petition

U.S. Patent No. 10,947,257

Folen, V.A. X-Ray Powder Diffraction... J. Forensic Science, Apr. 1975, Vol. 20, No. 2.

Nichols, D.E. Psychedelics, Pharmacol Rev 68, April 2016, 264-355.

Guo M. et ano. Potential Application of Silicified Microcrystalline..., .Pharmaceutical Development And Technology Vol. 8, No. 1, 2003, 47-59

Curriculum Vitae-Sven Lidin, Ph.D.

Curriculum Vitae-James A. Kaduk, Ph.D.

Declaration of Raj Suryanarayanan, Ph.D.

Curriculum Vitae-Raj Suryanarayanan, Ph.D.

Hancock B. et ano. Characteristics and Significance of the Amorphous...,.Journal of Pharmaceutical Sciences, Volume 86, Number 1, January, 1997

Arlin, J.B. et al. Experimental Crystal Structure Determination, 1-3, 2021

Bernstein J. Polymorphism in Molecular Crystals, International Union Of Crystallography, Oxford, 2002

Boratto, M. H. Semiconducting and Insulating Oxides Applied to Electronic Devices, Thesis, Ph.D. - Post Graduate Program in Materials Science and Technology, UNESP, School of Science, Bauru, 2018

D.E. Nichols, Synthesis of High Purity Psilocybin: Lot 10415-25, Nov. 1, 2009

June 6, 2012 letter from D. Nichols to R. Griffiths.

April 15, 2014 letter from C. Kim to E. Elder.

Triclinic Labs Report, Characterization of Psilocybin, Dec. 2, 2021

Decision denying Post-Grant Review, PGR 2020-0030.

USP35-(941) Physical Tests X-Ray Powder Diffraction.

Ottoboni S. et al. Understanding API Static Drying .... Org. Process Res. Dev. 2020, 24, Oct. 16, 2020, 2505-2520.

Airaksinen S. et al. Comparison of the Effects of Two Drying Methods, International Journal of Pharmaceutics 276 (2004) 129-141.

Lim H.L. et al, Understanding and Preventing Agglomeration in a Filter Drying Process, Powder Technology, 300 (2016) 146-156.

Curriculum Vitae-Charles L. Raison, M.D.

Excerpt from Diagnostic and Statistical Manual of Mental Disorders, Am. Psychiatric Assn. 5th Ed. 2013.

Excerpt from Dictionary of Chemistry 6th Edition.

Astrazeneca AB v. Reddy's Laboratories, Inc., No. 11-2317, 2013 U.S. Dist. LEXIS 62149 (May 1, 2013)

Baker R. W. et al. Molecular Structures of Hallucinogenic Substances...Molecular Pharmacology, 9, 1973, 23-32

Petcher, T. J. et ano. Crystal Structures of the Teonanhcatl Hallucinogens, J. Chem Soc. Perkins Trans. 2, 8,1974.

Kuhnert-Brandstatter M. et ano. Polymorphe Modifikationen und Solvate von Psilocin und Psilocybin, Arch. Pharm, 1976

Hofmann A. et al. Psylocybin and Psilocin, Fasciculus, Vol. XLII,1959, 167-168.

U.S. Patent No. 3,192,111

U.S. Patent No. 3,183,172

Nichols D. E et ano. Improvements to the Synthesis of Psilocybin.. Synthesis 1999, No. 6, 935-938.

Kargbo R. B. et al. Direct Phosphorylation of Psilocin..., ACS Omega 2020, 5, 16959-16966.

Sherwood A. M. et al. An Improved, Practical, and Scalable...Synthesis 2020, 52, 688-694.

dos Santos et al. Antidepressive, Anxiolytic....Ther Adv Psychopharmacol, 2016, Vol. 6 (3) 193-213.

Hill R. J. Expanded Use of the Rietveld Method... Powder Diffraction, Vol. 6, No. 2, June 1991.

Groom C.R. et al. The Cambridge Structural Database, Acta Cryst. (2016). B72, 171-179.

Lee P. L. et al. A Twelve-Analyzer Detector System, J. Synchrotron Rad. (2008). 15, 427-432.

Wang J. et al. A Dedicated Powder Diffraction Beamline.., Review of Scientific Instruments 79, 085105 (2008).

Antao S. M. et al. State-Of-The-Art High-Resolution Powder.., The Canadian Mineralogist, Vol. 46, (2008) 1501-1509.

Toby B. H. et ano. GSAS-II The Genesis of a Modern Open-Source.., J. Appl. Cryst. (2013) 46, 544-549.

Sykes R. A. et al. New software for Statistical Analysis..,.J. Appl. Cryst. (2011) 44, 882-886.

Bruno I. J. et al. Retrieval of Crystallographically-Derived Molecular Geometry Information, J. Chem. Inf. Comput. Sci. 2004, 44, 2133-2144.

Kresse G. et ano. Efficiency of Ab-Initio Total Energy Calculations..., Computational Materials Science 6 (1996) 15-50.

Dovesi R. et al. Quantum-mechanical Condensed Matter Simulations.., WIREs Comput. Mol Sci. 2018, 1-36.

Gatti C. et al. Crystal Field Effects On The Topological Properties.., J. Chem. Phys. 101, 10686 (1994).

Peintinger M.F. et al. Consistent Gaussian Basis Sets of Triple-Zeta., Journal of Computational Chemistry 2012, 1-9.

Louer D. et ano. Some Further Considerations In Powder Diffraction.., Powder Diffraction 29 (S2), December, 2014.

Kourkoumelis K. Powdll a Reusable .net Component for.., Powder Diffr., Vol. 28, No. 2, June 2013, 142.

Curriculum Vitae-Roland R. Griffiths Ph.D.

Zeeh Pharmaceutical Experiment Station Certificate of Analysis for Lot No. 10415-25.

Barrett F. S. et al. Double-blind Comparison of the Two Hallucinogens Psilocybin..., Psychopharmacology (Berl). 2018 October, 235 (10) 2915-2927.

August 13, 2020, Non-Final Office Action re: U.S. Patent Application No. 16/920,223

Applicant Initiated Interview Summary re: U.S. Patent Application No. 16/920,223

USPTO Amendment, November 13, 2020

Prabhu S. L. et ano. Impurities And Its Importance In Pharmacy, Int. Journal of Pharma. Sciences Review and Research, Vol. 3, Issue 2, July-August 2010, Article 012.

ICH Topic Q 3 A (R2) Impurities in new Drug Substances 2006.

Martin's Physical Pharmacy and Pharmaceutical Sciences, 2011

USPTO Amendment, Nov. 19, 2020

The Manufacturing Process, Solid Dose Experts Techceuticals, Vol. 15 (2015).

Documentation of shipment of sample from JHU Batch to Triclinic Labs.

Sixsmith, D. Effect of Compression on MCC, J. Pharm. Pharmac., 1977, 29, 33-36.

Curriculum Vitae-Brett D. Bobzien

Documentation of shipment of sample from JHU Batch to Triclinic Labs, Inc.

Altomare A. et al. Expo2013: A Kit Of Tools For Phasing Crystal Structures From Powder Data, Journal of Applied Crystallography, 2013.

Patra S. Return of the Psychedelics..... Asian Journal of Psychiatry 24, 2016, 51-52.

Grob C. et al. Pilot Study of Psilocybin Treatment for Anxiety, Arch Gen Psychiatry. 2011;68, 1, 71-78.

Ross S. et al. Rapid and Sustained Symptom Reduction.. Journal of Psychopharmacology, 2016, Vol. 30, 12, 1165-1180

Petzoldt C. et al. An Example of How to Handle Amorphous Fractions...European Journal of Pharmaceutics and Biopharmaceutics 86, 2014.

Siven M. et al. Challenge of Paediatric Compounding to Solid Dosage.. Journal of Pharmacy and Pharmac. 69, 2017, pp. 593-602

Tobyn M. et al. Physicochemical Comparison Between Microcrystalline... International Journal of Pharmaceutics 169, 1998, 183-194.

Packing Slip, JHU Pharmacy to Triclinic, 7-21-2021

Triclinic Labs Inc. SOP Controlled Substances.

Sherwood and Meinsenheimer Declaration filed in PGR2020-0030.pdf

Shirota et al. Concise Large-Scale Synthesis of Psilocin and Psilocybin, Principal Hallucinogenic Constituents of Magic Mushroom, Principal... J. Nat. Prod. 2003, 66, 885-887

USP Standards, 2000

Griffiths R.R. et al. Psilocybin Produces Substantial and Sustained Decreases in Depression ...Journal of Psychopharmacology, Vol. 30 (12) 1181 -1197.

POA for Post Grant Review of U.S. Patent No. 10,947,257

Sherwood, A.M., et al. Psilocybin: Crystal Structure Solutions Enable Phase Analysis Of Prior Art And Recently Patented Examples, 2022, Acta Cryst. C78

Declaration of James A. Kaduk, Ph.D.

Declaration of Charles L. Raison, M.D.

Declaration of Brett D. Bobzien

Declaration of Sven Lidin, Ph.D.

Excerpts of Handbook of Pharma Excipients.

Carhart-Harris R. et al. Psilocybin with Psychological Support..Lancet Psychiatry, www.thelancet.compsychiatry, 2016

Declaration of Roland R. Griffiths, Ph.D.

Petition for Post Grant Review of U.S. Patent No. 10,947,257.